HK1060875A1 - Tetralone derivatives as antitumor agents - Google Patents

Tetralone derivatives as antitumor agents

Info

Publication number
HK1060875A1
HK1060875A1 HK04103910A HK04103910A HK1060875A1 HK 1060875 A1 HK1060875 A1 HK 1060875A1 HK 04103910 A HK04103910 A HK 04103910A HK 04103910 A HK04103910 A HK 04103910A HK 1060875 A1 HK1060875 A1 HK 1060875A1
Authority
HK
Hong Kong
Prior art keywords
antitumor agents
tetralone derivatives
tetralone
derivatives
antitumor
Prior art date
Application number
HK04103910A
Other languages
English (en)
Inventor
Guy Georges
Adelbert Grossmann
Tim Sattelkau
Wolfgang Schaefer
Ulrich Tibes
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1060875A1 publication Critical patent/HK1060875A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK04103910A 2000-12-07 2004-06-01 Tetralone derivatives as antitumor agents HK1060875A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126820 2000-12-07
PCT/EP2001/014311 WO2002046144A1 (en) 2000-12-07 2001-12-06 Tetralone derivatives as antitumor agents

Publications (1)

Publication Number Publication Date
HK1060875A1 true HK1060875A1 (en) 2004-08-27

Family

ID=8170594

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04103910A HK1060875A1 (en) 2000-12-07 2004-06-01 Tetralone derivatives as antitumor agents

Country Status (26)

Country Link
US (1) US6531472B2 (de)
EP (1) EP1349830A1 (de)
JP (1) JP4091431B2 (de)
KR (1) KR20030077551A (de)
CN (1) CN100340545C (de)
AR (1) AR035659A1 (de)
AU (2) AU2002216074C1 (de)
BG (1) BG107889A (de)
BR (1) BR0115988A (de)
CA (1) CA2430355A1 (de)
CZ (1) CZ20031833A3 (de)
EC (1) ECSP034642A (de)
HK (1) HK1060875A1 (de)
HR (1) HRP20030451A2 (de)
HU (1) HUP0400579A2 (de)
IL (1) IL156133A0 (de)
MA (1) MA26972A1 (de)
MX (1) MXPA03004947A (de)
NO (1) NO20032531L (de)
NZ (1) NZ526051A (de)
PL (1) PL365324A1 (de)
RU (1) RU2288220C2 (de)
SK (1) SK8512003A3 (de)
WO (1) WO2002046144A1 (de)
YU (1) YU45803A (de)
ZA (1) ZA200304262B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
EP2269609A3 (de) * 2001-10-16 2012-07-11 Sloan-Kettering Institute for Cancer Research Behandlung von neurodegenerativen Erkrankungen und Gehirnkrebs mit Suberoylanilid-Hydroxyamsäure (SAHA)
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
CA2632078C (en) 2002-03-04 2012-08-14 Sloan-Kettering Institute For Cancer Research Methods of inducing terminal differentiation
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
EP1492596A1 (de) * 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptid zur behandlung von nierenkrebs
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006509010A (ja) * 2002-12-05 2006-03-16 インペリアル・カレッジ・イノベイションズ・リミテッド アポトーシスの制御
JP2006520796A (ja) * 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
CN102188415A (zh) 2003-08-26 2011-09-21 默克Hdac研究有限责任公司 用hdac抑制剂治疗癌症的方法
CA2535889A1 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US20050288215A1 (en) * 2004-04-05 2005-12-29 Mckinsey Timothy A Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
WO2005099747A1 (en) * 2004-04-14 2005-10-27 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
KR100632800B1 (ko) 2004-10-21 2006-10-16 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 신규한하이드록시아마이드 유도체 및 이의 제조 방법
EP1824831A2 (de) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
WO2006122319A2 (en) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
TWI415603B (zh) 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
JP2009501236A (ja) * 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2012801A4 (de) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc Gemcitabin-kombinationstherapie
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP3052662B1 (de) 2013-10-01 2019-05-15 The J. David Gladstone Institutes Zusammensetzungen, systeme und verfahren für genexpressionsrauschen-wirkstoffscreening und verwendungen davon
EP3062783B1 (de) * 2013-10-18 2020-08-12 The General Hospital Corporation Bildgebung von histondeacetylasen mit einem radiotracer mittels positronenemissionstomografie
EP3461488A1 (de) 2017-09-27 2019-04-03 Onxeo Kombination aus einem dbait-molekül und einem hdac-inhibitor zur behandlung von krebs
EP3461480A1 (de) 2017-09-27 2019-04-03 Onxeo Kombination von checkpoint-hemmern des dna-schädigungsantwort-zellzyklus und belinostat zur behandlung von krebs
TWI799691B (zh) * 2019-03-29 2023-04-21 景凱生物科技股份有限公司 具有側鏈烷基與烯基延伸的苯基衍生物及包括有其的藥學組合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4405680A1 (de) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur verbesserung der wirksamkeit einer hdac-hemmertherapie und vorhersage der reaktion auf die behandlung mit hdac-hemmer
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448730A (en) * 1981-03-24 1984-05-15 Riet Bartholomeus Van T Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5637946A (en) * 1993-10-28 1997-06-10 Lockheed Corporation Thermally energized electrical power source
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds

Also Published As

Publication number Publication date
NO20032531D0 (no) 2003-06-04
NZ526051A (en) 2004-12-24
EP1349830A1 (de) 2003-10-08
YU45803A (sh) 2006-05-25
ECSP034642A (es) 2003-07-25
NO20032531L (no) 2003-06-04
AU1607402A (en) 2002-06-18
CN100340545C (zh) 2007-10-03
HUP0400579A2 (hu) 2004-06-28
WO2002046144A1 (en) 2002-06-13
US20020065282A1 (en) 2002-05-30
BG107889A (bg) 2004-06-30
JP4091431B2 (ja) 2008-05-28
MXPA03004947A (es) 2003-09-10
HRP20030451A2 (en) 2005-04-30
CA2430355A1 (en) 2002-06-13
KR20030077551A (ko) 2003-10-01
MA26972A1 (fr) 2004-12-20
CZ20031833A3 (cs) 2004-02-18
ZA200304262B (en) 2004-08-30
BR0115988A (pt) 2004-01-13
AU2002216074C1 (en) 2006-12-07
PL365324A1 (en) 2004-12-27
AR035659A1 (es) 2004-06-23
IL156133A0 (en) 2003-12-23
CN1478072A (zh) 2004-02-25
SK8512003A3 (en) 2004-04-06
JP2004515488A (ja) 2004-05-27
AU2002216074B2 (en) 2006-01-05
US6531472B2 (en) 2003-03-11
RU2288220C2 (ru) 2006-11-27

Similar Documents

Publication Publication Date Title
AU1607402A (en) Tetralone derivatives as antitumor agents
HK1066218A1 (en) Qunazoline derivatives as antitumor agents
AU7306201A (en) Substituted-triazolopyrimidines as anticancer agents
EG22695A (en) Novel phenyl-propargylether derivatives
IL152783A0 (en) 2-aminocarbonyl-9h-purine derivatives
HRP20030055A2 (en) 4-phenyl-pyridine derivatives
IL150841A0 (en) 1h-imidazopyridine derivatives
AU2002224595A1 (en) Antitumor agents
HK1061018A1 (en) Substituted c-cyclohexylmethylamine derivatives
IL155106A0 (en) Substituted 1-aminobutan-3-ol derivatives
IL150557A0 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
HK1052499A1 (zh) 氨基磺酰基聯苯基衍生物
IL150558A0 (en) Aminomethyl-phenyl-cyclohexanone derivatives
AU2163202A (en) 5-amino-1-pentene-3-ol substituted derivatives
IL151598A0 (en) 2-phenylpyran-4-one derivatives
GB0021639D0 (en) Maurotoxin derivatives
HK1054937A1 (en) 1-Methylcarbapenem derivatives
SI1246793T1 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
SI1322590T1 (sl) Substituirani 5-amino-1-penten-3-olni derivati

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111206